FMP

FMP

Enter

TCON - TRACON Pharmaceutica...

Financial Summary of TRACON Pharmaceuticals, Inc.(TCON), TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercial

photo-url-https://financialmodelingprep.com/image-stock/TCON.png

TRACON Pharmaceuticals, Inc.

TCON

NASDAQ

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

1.89 USD

0.04 (2.12%)

About

ceo

Dr. Charles P. Theuer M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.traconpharma.com

exchange

NASDAQ

Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I...

CIK

0001394319

ISIN

US89237H2094

CUSIP

89237H209

Address

4350 La Jolla Village Drive

Phone

858 550 0780

Country

US

Employee

17

IPO Date

Jan 30, 2015

Summary

CIK

0001394319

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

89237H209

ISIN

US89237H2094

Country

US

Price

1.89

Beta

0.79

Volume Avg.

238k

Market Cap

86M

Shares

-

52-Week

1.59-17.6

DCF

0.56

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-17.18

P/B

-

Website

https://www.traconpharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest TCON News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep